Krystal Biotech, Inc. (KRYS) - Comprehensive Stock Analysis & Investment Research
Deep dive into Krystal Biotech, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Krystal Biotech, Inc. Investment Summary
When evaluating whether Krystal Biotech, Inc. (KRYS) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Krystal Biotech, Inc. (KRYS) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $10 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.
Financial Performance Analysis
Our comprehensive financial analysis covers Krystal Biotech, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Krystal Biotech, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Krystal Biotech, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Krystal Biotech, Inc. (Stock Symbol: KRYS) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Krystal Biotech, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Krystal Biotech, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Krystal Biotech, Inc....
Revenue & Growth Analysis
Krystal Biotech, Inc. generates annual revenues of $417 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Krystal Biotech, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Krystal Biotech, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Krystal Biotech, Inc....
Strategic Market Position
Krystal Biotech, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.
Industry Competitive Landscape
Krystal Biotech, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company shows positive operational efficiency through free cash flow generation of $237 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.
Asset Utilization Efficiency
Asset turnover ratio of 0.30x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.
Financial Strength & Leverage
Current ratio of 9.46 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.